Skip to main content
Healthcare

New study supports testing of Merck’s Ebola vaccine in DRC outbreak

MAP Verified Summary — reported by STAT News

New data supports the idea that Merck’s Ebola vaccine Ervebo, licensed to target the Zaire species of ebolaviruses, could also offer some protection against another.

This story’s context record documents 7 observable dimensions — Origin, Attribution, Specificity, Timing, Framing, Context Change, and Information Relationships — as part of Media Alert Press’s context-documentation ledger. MAP does not score or rate this content. Read the full original story at STAT News →


Discover more from Media Alert Press

Subscribe to get the latest posts sent to your email.

Original Source

This article was syndicated from STAT News. All rights remain with the original publisher.